You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

isatuximab

Showing 1 - 25 of 70
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Antibody-mediated Rejection, Allosensitization Trial in New York (Isatuximab, bone marrow biopsy)

Not yet recruiting
  • Antibody-mediated Rejection
  • Allosensitization
  • Isatuximab
  • bone marrow biopsy
  • New York, New York
    NYU Langone Health
May 16, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Isatuximab
  • +3 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 8, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Isatuximab
  • +3 more
  • (no location specified)
Feb 3, 2023

Plasma Cell Myeloma Trial (Isatuximab (SAR650984), Cemiplimab (SAR439684), Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • Isatuximab (SAR650984)
  • +4 more
  • (no location specified)
Feb 1, 2023

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • (no location specified)
Jul 3, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)

Withdrawn
  • Amyloidosis
  • Light Chain (AL) Amyloidosis
  • Bendamustine Hydrochloride
  • Isatuximab
  • (no location specified)
Dec 29, 2022

Platelet Refractoriness, Hematologic Malignancy Trial in Charlottesville (isatuximab 10 mg/kg)

Recruiting
  • Platelet Refractoriness
  • Hematologic Malignancy
  • isatuximab 10 mg/kg
  • Charlottesville, Virginia
    University of Virginia
Jan 27, 2023

Monoclonal Gammopathy Trial in New York, Philadelphia (Isatuximab)

Recruiting
  • Monoclonal Gammopathy
  • Isatuximab
  • Boston, Massachusetts
  • +1 more
Nov 16, 2022

Multiple Myeloma, Myeloma Multiple, Myeloma Trial in Poitiers (Drug and medical device)

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Drug and medical device
  • Poitiers, France
    CHU Poitiers
Jun 1, 2023

Multiple Myeloma Trial in Stockholm (CellProtect, Isatuximab)

Recruiting
  • Multiple Myeloma
  • Stockholm, Sweden
    Karolinska University Hospital, Huddinge
Aug 16, 2022

Multiple Myeloma Trial in Saint Louis (Isatuximab, Bendamustine, Prednisone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 21, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Isatuximab
  • +3 more
  • Poitiers, France
    CHU Poitiers
Jan 9, 2023

Multiple Myeloma Trial in Beijing, Nanjing, Tianjin (Isatuximab SAR650984)

Active, not recruiting
  • Multiple Myeloma
  • Isatuximab SAR650984
  • Beijing, China
  • +2 more
Aug 22, 2022

Blood Cancer, Refractory Immune Cytopenias Trial in United States (Isatuximab)

Not yet recruiting
  • Blood Cancer
  • Refractory Immune Cytopenias
  • Isatuximab
  • Basking Ridge, New Jersey
  • +6 more
May 15, 2023

Immunological Pure Red Cell Aplasia Trial (Isatuximab)

Not yet recruiting
  • Immunological Pure Red Cell Aplasia
  • Isatuximab
  • (no location specified)
Sep 26, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Isatuximab
  • +2 more
  • Chapel Hill, North Carolina
  • +2 more
Jun 9, 2023

Multiple Myeloma Trial (Isatuximab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 19, 2022

Multiple Myeloma Trial in Milwaukee (Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Isatuximab (for run-in portion)
  • +4 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Feb 18, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Multiple Myeloma Trial in Saint Louis (Isatuximab, Bortezomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 4, 2022

Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jan 10, 2023

Multiple Myeloma Trial in Oslo, Stavanger, Trondheim (Isatuximab, bortezomib, lenalidomide, dexamethason)

Recruiting
  • Multiple Myeloma
  • Isatuximab, bortezomib, lenalidomide, dexamethason
  • Roskilde, Denmark
  • +3 more
Sep 20, 2022